Why These 24 Stocks Are Skyrocketing

Page 14 of 23

10. Chimerix, Inc. (NASDAQ:CMRX)

Q4 Returns as of December 31, 2024: 274%

CMRX surged 274% in the last quarter of 2024, underscoring investor optimism. As of January 10, the stock had jumped by 257% over the past year.

The biotechnology company is committed to developing innovative medicines for cancer and other serious diseases and improving the lives of patients. Over the past few months, the company has displayed accelerated performance in trials and has shown commitment to expanding its product pipeline.

Chimerix’s (CMRX) novel drug, Dordaviprone- which holds the potential to treat patients with H3 K27M-mutant diffuse glioma- is currently being evaluated for phase 3 trials and is expected to release partial data by the third quarter of 2025.

Analysts have shared a bullish sentiment on the stock, with their median price target of $8 implying an upside of 121% from current levels.

Page 14 of 23